**Abstract**—Although rare, stent thrombosis remains a severe complication after stent implantation owing to its high morbidity and mortality. Since the introduction of drug-eluting stents (DES), most interventional centers have noted stent thrombosis up to 3 years after implantation, a complication rarely seen with bare-metal stents. Some data from large registries and meta-analyses of randomized trials indicate a higher risk for DES thrombosis, whereas others suggest an absence of such a risk. Several factors are associated with an increased risk of stent thrombosis, including the procedure itself (stent malapposition and/or underexpansion, number of implanted stents, stent length, persistent slow coronary blood flow, and dissections), patient and lesion characteristics, stent design, and premature cessation of antiplatelet drugs. Drugs released from DES exert distinct biological effects, such as activation of signal transduction pathways and inhibition of cell proliferation. As a result, although primarily aimed at preventing vascular smooth muscle cell proliferation and migration (ie, key factors in the development of restenosis), they also impair reendothelialization, which leads to delayed arterial healing, and induce tissue factor expression, which results in a prothrombogenic environment. In the same way, polymers used to load these drugs have been associated with DES thrombosis. Finally, DES impair endothelial function of the coronary artery distal to the stent, which potentially promotes the risk of ischemia and coronary occlusion. Although several reports raise the possibility of a substantially higher risk of stent thrombosis in DES, evidence remains inconclusive; as a consequence, both large-scale and long-term clinical trials, as well as further mechanistic studies, are needed. The present review focuses on the pathophysiological mechanisms and pathological findings of stent thrombosis in DES. (Circulation. 2007;115:1051-1058.)

**Key Words:** stents □ thrombosis □ pathology □ physiology □ risk factors □ arteries □ myocardial infarction

**Clinical Evidence**

Numerous reports describe the occurrence of acute (<24 hours), subacute (<30 days), late (>30 days), and very late (>12 months) stent thrombosis after DES implantation.8,13,16 However, the true incidence of stent thrombosis may be underestimated in clinical trials and could occur at substantially higher rates in the “real-world” setting, where more
complex lesions are treated.\textsuperscript{14,15} Given the small size of both clinical trials and registries and the low absolute number of stent thromboses, meta-analyses were performed to clarify this issue. Several meta-analyses initially did not reveal an increased risk of stent thrombosis with DES compared with BMS at 9 to 12 months.\textsuperscript{10,11,12} Subsequently, 3 additional meta-analyses attracted special attention: In a large analysis of >8000 patients from 2 academic referral hospitals, a substantial cumulative incidence of angiographically documented DES thrombosis was noted (2.9\%), yielding a rate of 1.3 per 100 patient-years.\textsuperscript{17} In that analysis, however, no patients with BMS were included, and hence, direct comparison of the 2 types of stents was not possible; given the change in percutaneous coronary intervention practice with DES, these data are difficult to interpret. In another study directly comparing DES and BMS, an increase in late thrombosis was noted in DES.\textsuperscript{16} Furthermore, a meta-analysis that included total mortality and Q-wave myocardial infarction as end points representing the “inclusive clinical surrogate of stent thrombosis” found an increased cumulative incidence of death or myocardial infarction at the latest available follow-up.\textsuperscript{9} Because coronary patients experience new occlusions at sites distant from the implanted stent and/or fatal arrhythmias, however, such an analysis may overestimate the true stent thrombosis rate. Moreover, interpretation of meta-analyses is restricted because of their inherent limitations, which include selective use of end points, incomplete data sets, and the retrospective nature of their analysis.

**Pathophysiology of In-Stent Thrombosis**

Several factors that contribute to stent thrombosis have been recognized, which are discussed below.

**Procedure-Related Factors**

Among the procedure-related factors, smaller final lumen dimensions (stent malapposition and/or underexpansion), stent length, persistent slow coronary blood flow, placement of multiple stents, positive remodeling, dissections, geographic miss, and late stent malapposition due to thrombus resolution appear to be most important for the development of in-stent thrombosis.\textsuperscript{19–25} Also, in DES, stent length, stent underexpansion, and residual stenosis have been observed to correlate with an increased risk for stent thrombosis.\textsuperscript{26,27} These factors are of great interest because they can be avoided during the intervention, but they are unlikely to differ between BMS and DES.

**Patient- and Lesion-Related Factors**

Several patient-related factors have been associated with the development of in-stent thrombosis, including low ejection fraction,\textsuperscript{21} diabetes mellitus,\textsuperscript{28} advanced age,\textsuperscript{22} and stenting in the setting of an acute coronary syndrome.\textsuperscript{26} Similarly, in DES, primary stenting in acute myocardial infarction, diabetes mellitus, renal failure, and low ejection fraction appear to be associated with an increased risk for stent thrombosis.\textsuperscript{14,26,29,30} In particular, the increased risk in patients with acute coronary syndrome could be due to delayed healing, lack of endothelialization, and presence of a pronounced inflammatory and thrombogenic environment of the exposed necrotic core to flowing blood, accompanied by enhanced platelet reactivity; furthermore, rapamycin and paclitaxel potentiate thrombin-induced expression of tissue factor (see below).

Furthermore, certain lesion characteristics are reported to be associated with an increased risk of stent thrombosis. In DES, this pertains in particular to stenting of bifurcation lesions or in-stent restenosis lesions.\textsuperscript{14,29,30} In addition, interventional practice has changed, with advocates of “normal to normal” coronary artery stenting and revascularization of more complex lesions that carry a higher risk of stent thrombosis. This latter aspect makes comparisons of registries with historical controls difficult.

**Antiplatelet Therapy**

Stents are foreign bodies in the vessel wall and thus induce platelet adhesion and activation of the coagulation cascade. Furthermore, high-pressure implantation with noncompliant balloons induces significant vascular injury, with exposure of thrombogenic molecules of the subintima and media (including plaque material) to the blood stream. As a consequence, only potent platelet inhibition made the procedure feasible, and antiplatelet hyporesponsiveness has been associated with an increased risk for stent thrombosis.\textsuperscript{31} In line with this observation, discontinuation of antiplatelet therapy has been observed to be particularly associated with DES thrombosis.\textsuperscript{8,16,32} The appropriate duration of the long-term antiplatelet regimen for prevention of DES thrombosis remains to be assessed in randomized prospective trials; at present, a course of 12 months of dual-antiplatelet therapy may be considered especially in high-risk, real-world patients.

**Thrombogenicity of the Stent**

A predisposition for the development of stent thrombosis has been observed with certain stent materials; for example, platelet activation was greater during the 30 days after implantation of an open-cell versus a closed-cell stent.\textsuperscript{33} Stent strut thickness and polymer type and thickness also play an important role. It has been reported previously that the nonerodable polymers of the Cypher and Taxus DES provoke chronic eosinophilic infiltration of the arterial wall, suggestive of hypersensitivity reactions in a small number of cases.\textsuperscript{7,34} However, the causal relationship between polymer-induced inflammation and the incidence of late stent thrombosis has only been proven in a minority of patients possessing a proinflammatory phenotype. Detailed analysis of the morphological changes shows a localized immune response, with predominance of CD45-positive lymphocytes and eosinophils. In fact, our experience shows that all cases of hypersensitivity occur >4 months after DES implantation.\textsuperscript{7} The preclinical experience in a pig model also shows a progressive increase in the presence of granulomatous reactions, including eosinophilic infiltrate, starting at 28 days after Cypher stent implantation: 1 month, 14\%; 3 months, 43\%; 6 months, 60\% (R.V., unpublished data). One possible explanation of these findings is that the hypersensitivity reaction peaks after the complete release of the drug and is likely related to the polymer. In addition, positive remodeling
has been observed in vessels showing a hypersensitivity reaction.

Furthermore, drugs loaded on DES may exert a prothrombogenic effect. Rapamycin (sirolimus), a macrocyclic lactone, is used on DES, because it is known to inhibit proliferation and migration of vascular smooth muscle cells, important factors in the development of neointima formation and restenosis, through interference with cell cycle regulators.35,36 On a subcellular level, rapamycin binds to the FK-binding protein 12 and subsequently inhibits the mammalian target of rapamycin. The mammalian target of rapamycin is a downstream target of the phosphatidylinositol-3 kinase pathway, which in turn is involved in an inhibitory fashion in the regulation of tissue factor in endothelial cells and monocytes.37–39 As a result, rapamycin inhibition of the mammalian target of rapamycin increases both thrombin- and tumor necrosis factor-α–induced endothelial tissue factor expression and activity at concentrations of rapamycin that are encountered in vivo (Figure 1).38,40

Paclitaxel is a lipophilic diterpenoid that binds to the β-subunit of the tubulin heterodimer, promoting tubulin polymerization, cell cycle arrest, and, eventually, inhibition of vascular smooth muscle cell migration and proliferation.41,42 In addition, paclitaxel is known to activate c-Jun NH2-terminal kinase,43,44 an important mediator of endothelial and monocytic tissue factor induction.47,39,45 Consequently, paclitaxel also enhances tissue factor expression and activity in endothelial cells;44,46 again, concentrations used in this in vitro study are comparable with local tissue concentrations of paclitaxel after stent deployment.46

In sirolimus-eluting stents, ≈80% of the rapamycin has eluted by 30 days, whereas paclitaxel-eluting stents have a biphasic drug release profile in vitro with an initial burst during the first 48 hours after implantation followed by a sustained low-level release for at least 2 weeks.45 However, both rapamycin and paclitaxel easily penetrate into cells of the vessel wall owing to their lipophilic properties, which leads to chronic retention of the drug in the arterial tissue.6,19,46,48 Thus, both rapamycin- and paclitaxel-induced tissue factor expression may contribute to a prothrombotic environment after deployment of DES, particularly in the acute and subacute setting and possibly in late stent thrombosis (Figure 1). The relationship between these findings and stent thrombosis in clinical practice requires further study, particularly to examine the degree and the spatiotemporal pattern of tissue factor expression in the arterial wall after deployment of DES.

**Impaired Reendothelialization**

Reendothelialization occurs after vascular injury and similarly after stent placement. Traditionally, it was believed that endothelial cells proliferate and migrate from intact neighboring coronary segments, eventually leading to the reendothelialization of the injured segment. In vitro, rapamycin and paclitaxel not only inhibit proliferation and migration of vascular smooth muscle cells but equally suppress endothelial cells,7,35,36,38,49–51 thereby potentially impeding reendothelialization (Figure 2). We observed poor endothelial cell junction formation and microthrombi of focal platelet aggregation at 16 months after rapamycin stent implantation in a patient dying of a non-DES–related cause.52 It has been proposed that bone marrow–derived endothelial progenitor cells may also be involved in reendothelialization.53,54 Interestingly, rapamycin inhibits proliferation, migration, and differentiation of human endothelial progenitor cells in vitro.55,56 Hence, drugs loaded on DES may affect the number as well as the homing and proliferation of endothelial progenitor cells, thus further preventing proper endothelial healing (Figure 2).

In vivo, the time course of endothelial healing after stent implantation varies in different animal models. Although in healthy pigs, reendothelialization is similar between BMS and DES at 28 days,48 a clear delay of endothelialization in both sirolimus- and paclitaxel-eluting stents was observed in a rabbit iliac-overlapping DES implantation model.46 In view of distinct differences with respect to vessel wall reactivity after stent implantation between animals and humans, however, these results cannot be applied entirely to the situation in humans. After BMS implantation, near-complete endothelialization has been suggested to occur by 3 to 4 months.6 A morphological autopsy study comparing coronary segments from patients after DES and BMS implantation revealed delayed arterial healing and poorer endothelialization after DES compared with BMS implantation of similar duration (Figure 3).7 Indeed, in 23 DES patients in that study, 14 had evidence of late-stent thrombosis, and of these 14 patients, 13 died of a DES-related cause.7 Thus, current evidence suggests delayed reendothelialization and arterial healing after implantation of DES compared with BMS, resulting in potentially
enhanced thrombogenicity (Figure 4). It is uncertain whether reendothelialization with DES is only delayed or persistently incomplete up to late time points. It is unclear in atherosclerotic human arteries how long it will take for DES to endothelialize. We have shown that in humans, delayed healing is common with current DES and that in those that thrombose, other factors, such as hypersensitivity reaction, bifurcating and ostial stenting, penetration of

Figure 2. DES reduce neointima formation but may increase stent thrombogenicity. Effect of sirolimus-eluting/paclitaxel-eluting stent strut on the local vessel wall after implantation. Sirolimus/paclitaxel reduces neointima formation by inhibiting vascular smooth muscle migration and proliferation (green arrows). However, the drugs also inhibit reendothelialization, induce tissue factor (TF), and may prevent homing and proliferation of endothelial progenitor cells (EPCs; red arrows/bars).

Figure 3. Delayed reendothelialization after DES implantation. Time course of arterial healing in BMS, Taxus DES, and Cypher DES from 1 to 8 months after stent implantation. Although some peristrut inflammation is observed in BMS at 1 month, complete arterial healing, including a well-established neointimal layer, is seen at 3 and 8 months’ duration. Taxus DES shows early fibrin deposition surrounding stent struts (*), which persists up to 8 months, as a sign of delayed healing. In contrast, Cypher DES shows predominance of inflammatory cells, including giant cell formation (black arrowheads), at early time points (1 and 3 months), whereas fibrin deposition is stronger at 8 months.
a necrotic core, stent malapposition, and restenosis, may also be important predictors of thrombosis.

There is compelling evidence that certain subsets of patients have a favorable long-term outcome after implantation of DES, which results in a reduced need for interventional or surgical revascularization due to sustained suppression of neointimal growth. Factors associated with greater healing from our experience include shorter stent length, less plaque area, less fibrin deposition, and greater endothelialization. Other factors that may influence healing are likely to be patient-related, such as antiplatelet therapy discontinuation, renal failure, diabetes mellitus, and a lower ejection fraction, which have all been reported in clinical studies.14 Furthermore, there is variability from patient to patient even in wound healing; the response to drug also varies, with some patients requiring a lower drug dose for equivalent benefit. Thus, many factors influence the healing process and vary with individual risk factors.

Risk Factors for Different Time Points of DES Thrombosis
Stent thrombosis may occur acutely (within 24 hours of stent placement), subacutely (up to 30 days after stent implantation), as late thrombosis (after 30 days), or as very late thrombosis (after 12 months). The most important risk factors for acute and subacute stent thrombosis are primary stenting in ST-segment elevation myocardial infarction and acute coronary syndromes.20,26 Additional risk factors include stent length, congestive heart failure, and a prothrombogenic state, such as metastatic cancer.19,20,26,27 One of the most significant risk factors for late and very late stent thrombosis appears to be discontinuation of antiplatelet therapy.26,27 Other predictors are stent underexpansion and residual reference segment stenosis.19,27

Design of Future DES
The stent coating influences thrombogenicity. Whether a simple chemical coating, such as titanium-nitride-oxide, that diminishes platelet adhesion and fibrinogen binding compared with stainless steel will be effective against restenosis and stent thrombosis remains to be elucidated in large clinical trials.57 Coating of stents with substances that potentially facilitate reendothelialization may represent a novel therapeutic approach. For example, in preliminary studies, coating of stents with CD34 antibodies designed to “capture” endothelial progenitor cells proved to accelerate endothelial coverage and appeared safe and feasible in humans.58 Similarly, stents loaded with an integrin-binding cyclic Arg-Gly-Asp peptide accelerated endothelialization by attracting endothelial progenitor cells in a porcine model.59 Further studies are needed to assess the long-term efficacy and safety of these biologically active stents. Furthermore, a combination of “prohealing” substances (such as vascular endothelial growth factor) with established “antirestenosis” drugs may represent an interesting approach to obtain the benefit of reduced restenosis without the cost of an increased risk for stent thrombosis.

Considering the delay in healing along with the unknown time of reendothelialization of current DES, prohealing strategies such as the use of peroxisome proliferator-activated receptor-γ agonists, which not only diminish inflammation but also enhance endothelialization, may also represent an interesting new approach for DES.60 Given the importance of tissue factor in the initiation of coagulation and thrombosis, we also proposed dimethyl sulfoxide as a novel coating strategy for DES.61 Dimethyl sulfoxide prevents vascular smooth muscle cell proliferation and migration, ie, the key mechanisms of restenosis; at the same time, dimethyl sulfoxide inhibits tissue factor upregulation in endothelial cells, vascular smooth muscle, and monocytes and prevents thrombotic occlusion in a mouse carotid injury model.61

Conclusions
The pathogenesis of stent thrombosis is still not fully understood. A combination of factors may be involved, including procedure-related factors, patient-related factors, and lesion...
characteristics. With DES, biological properties such as thrombogenicity, ie, induction of tissue factor, inhibition of reendothelialization of the stented segment, and distal endo-
thelial dysfunction may increase the risk beyond that seen
with BMS. Because premature cessation and resistance to
antiplatelet drugs is associated with subacute and late DES
thrombosis, prolonged dual-platelet inhibition must be con-
sidered, especially in high-risk patients, balanced against the
risk of bleeding.

With nearly 6 million DES implanted, and in view of the
high morbidity and mortality associated with it, stent thrombosis is an important healthcare issue that requires further
clinical study. Consistent with this interpretation, the US
Food and Drug Administration issued a statement acknowl-
edging the importance of the increasing concern with respect
to DES thrombosis. There was consensus that the on-label use
of DES may be associated with a small increase in stent
thrombosis compared with bare-metal stents, but that it does
not lead to an increased risk of death or myocardial infarction,
and that under these conditions, the benefits of DES outweigh
a possibly increased risk for stent thrombosis; the panel left
open the possibility, however, that off-label use of DES (ie,
use of DES outside the FDA-approved indications) may
indeed be associated with an increased risk of death or
myocardial infarction compared with the use of BMS owing
to an increase in the rate of stent thrombosis.

Statements that second-generation DES appear to be less
prone to stent thrombosis and thus “safer” than first-
generation DES appear equally premature because the same
uncertainty with respect to long-term safety prevails. Addi-
tional in vitro studies of compounds used on DES and
autopsy studies of patients with DES dying of cardiac and
noncardiac causes would help in understanding the mecha-
nisms of stent thrombosis. Moreover, large-scale, non–
corporate-sponsored registries and clinical trials are needed to
reliably assess the “true” risk of stent thrombosis with DES.
Control of data by non–corporate-sponsored data analysis
centers under the auspices of the American Heart Associa-
tion/American College of Cardiology/European Society of
Cardiology, including cardiac surgeons, cardiologists, inter-
nists, and cardiac pathologists, is a prerequisite to the unbi-
ased evaluation of current and future DES technologies.

Sources of Funding
Research of the authors was supported by the Swiss National
Research Foundation (grant No. 3100-068118.02/1 to Dr Lüscher
and 3200Bo-113328/1 to Dr Tanner) and by the European Union
(grant No. G5RD-CT-2001-00532 to Dr Lüscher) and the Bonizzi-
Theler Stiftung (to Dr Steffel and Dr Tanner). The authors received
unrestricted research grants from Cordis, Biotronik, Boston Scien-
tific, and Medtronic (Dr Lüscher and Dr Eberli). Dr Virmani has
received research grants from companies including Medtronic, Ab-
bott, Guidant, and Cordis.

Disclosures
Dr Lüscher and Dr Tanner hold a patent on the potential clinical
applications of dimethyl sulfoxide. Dr Virmani is a consultant to
Medtronic and Guidant. The remaining authors report no conflicts.

References
1. Serruys PW, de Jaegere P, Kiemenej F, Macaya C, Rutsch W,
Heyndrickx G, Emanuelsen H, Marco J, Legrand V, Materne P, Belardi
M-A; Benestent Study Group. A comparison of balloon-expandable-stent
implantation with balloon angioplasty in patients with coronary artery
2. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre
K, Veltli L, Ricci D, Nobuyoshi M, Cleman M, Heuser R, Almond D,
Teirstein PS, Fish RD, Colombo A, Brinker J, Moses J, Shakhnovich A,
Hirshfeld J, Bailey S, Ellis S, Rake R, Goldberg S; Stent Restenosis Study
Investigators. A randomized comparison of coronary-stent placement and
3. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M,
A randomized comparison of a sirolimus-eluting stent with a standard
4. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR,
O’Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS,
Jaeger JL, Kuntz RE. Sirolimus-eluting stents versus standard stents in
349:1315–1323.
of the safety of clopidogrel with and without a loading dose in combi-
nation with aspirin compared with ticlopidine in combination with aspirin
after coronary stenting: the Clopidogrel Aspirin Stent International Coop-
6. Farb A, Burke AP, Kolodgie FD, Virmani R. Pathological mechanisms of
fatal late coronary stent thrombosis in humans. Circulation. 2003;108:
1701–1706.
Skorjia K, Gold HK, Virmani R. Pathology of drug-eluting stents in
8. McFadden EP, Stabile E, Reger E, Cheneau E, Ong AT, Kinnaird T,
Suddath WO, Weissman NJ, Torusgun R, Kent KM, Pichard AD, Slatzer
LF, Waksman R, Serruys PW. Late thrombosis in drug-eluting coronary
stents after discontinuation of antiplatelet therapy. Lancet. 2004;364:
1519–1521.
9. Camenzind E, Steg PG, Wijns W. Safety of drug-eluting stents: a meta-
analysis of 1st generation DES programs. Abstract presented at:
World Congress of Cardiology 2006, September 2–6, 2006, Barcelona, Spain.
stent thrombosis: results from a pooled analysis including 10 randomized
11. Bavry AA, Kumbhani DJ, Hettgen TJ, Bhatt DL. What is the risk of stent
thrombosis associated with the use of paclitaxel-eluting stents for percu-
12. Bavry AA, Kumbhani DJ, Hettgen TJ, Bhatt DL. Risk of thrombosis with
the use of sirolimus-eluting stents for percutaneous coronary intervention
13. FDA advises physicians of adverse events associated with Cordis Cypher
coronary stents. US Food and Drug Administration Public Health Web
14. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G,
Airoldi F, Chieffo A, Montorfano M, Carlinello M, Mischev I, Corvaja N,
Briguori C, Gerckens U, Colombo A, Incidence, predictors, and
outcome of thrombosis after successful implantation of drug-eluting stents.
15. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT,
Serruys PW. Late angiographic stent thrombosis (LAST) events with
16. Pflisterer ME, Kaiser CA, Bader F, Brunner-La Rocca HP, Bonetti PO,
Buser PT Late clinical events related to late stent thrombosis after stopping
clopidogrel: prospective randomized comparison between drug-
thrombosis versus bare-metal stenting. In: Program and abstracts from
the American College of Cardiology 55th Annual Scientific Session; March
11–14, 2006; Atlanta, Ga. Abstract 422-11.
17. Daemen J, Wenaewers P, Tsuchida K, Vaina S, Abrecht L, Morger C,


Drug-Eluting Stent and Coronary Thrombosis: Biological Mechanisms and Clinical Implications
Thomas F. Lüscher, Jan Steffel, Franz R. Eberli, Michael Joner, Gaku Nakazawa, Felix C. Tanner and Renu Virmani

Circulation. 2007;115:1051-1058
doi: 10.1161/CIRCULATIONAHA.106.675934

Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2007 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/115/8/1051

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org/subscriptions/